财中社12月31日电华润医药(03320)发布公告,宣布与华润集团签订了2025年采购框架协议和2025年产品及商品销售框架协议,协议有效期为2025年1月1日至2027年12月31日。这些协议是由于2023/2024年相关协议即将到期而重新签订的。根据公告,华润集团为公司的控股股东,间接持有约53.05%的权益,因此这些交易构成公司的持续关联交易。
根据上市规则,2025年采购框架协议和2025年产品及商品销售框架协议的年度上限的适用百分比率均低于5%,因此仅需遵守申报、公告及年度审阅的规定,无需独立股东批准。2025年采购框架协议下,拟进行交易的年度上限为每年1.55亿元的物资及产品采购和5000万元的服务采购。2025年产品及商品销售框架协议下,拟进行交易的年度上限为每年1.2亿元的销售额。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.